Company Announcement / Press release Archives

Xspray Pharma to host a conference call regarding Nilopki™

Xspray Pharma invites investors, analysts and media to a conference call (in English) on Monday, June 8, 2026, at 3:00 PM CET due to the news communicated on the night of today June 5, regarding the CRL received from the FDA for Nilopki™. The conference call will be hosted by CEO Blake Leitch and CSO […]

Xspray Pharma Receives CRL from U.S. FDA for Nilopki™

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology platform to develop improved versions of marketed protein kinase inhibitors (PKIs) for cancer treatment, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Nilopki™, an optimized formulation […]

Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead

Xspray Pharma’s two newly implemented long-term incentive programs, LTIP 2025/2028 and LTIP 2026/2029, have reached full participation from the employees to whom they were offered. Participating employees paid a calculated market price, and every warrant offered was taken up in full. The programs mature from May 2028 onwards with subscription prices of SEK 49.30 and […]

Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026

The following resolutions were passed at the annual general meeting (the “AGM”) of Xspray Pharma AB (publ) (“Xspray”) on 12 May 2026. Adoption of income statement and balance sheet for the financial year 2025 and discharge from liabilityThe AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2025 […]

New number of shares and votes in Xspray Pharma after new share issue April 2026

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) today announces that the number of shares and votes in Xspray Pharma AB has changed. New shares have been issued as a result of the rights issue and over-allotment issue announced on March 24, 2026. On March 26, 2026, the Board of Directors also decided to increase the over-allotment […]

Interim Report First Quarter 2026

January–March 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -35,380 thousand (-42,321) Earnings per share before dilution amounted to SEK -0.85 (-1.14) Cash flow from operating activities amounted to SEK -30,676 thousand (-66,329) Cash flow from investing activities amounted to SEK -1,067 thousand (-14,701) Amounts in parentheses […]

Xspray’s rights issue oversubscribed – over-allotment issue fully utilized

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL […]

FDA accepts trade name Nilopki® for Xspray’s drug candidate XS003 (nilotinib)

The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib (Tasigna®) for the treatment of chronic myeloid leukemia (CML), developed on Xspray's proprietary HyNap™ platform. Upon market approval, Xspray plans to launch Nilopki® in the US […]

Notice of annual general meeting of Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), Reg. No. 556649-3671, (”Xspray Pharma”) are summoned to the annual general meeting on Tuesday 12 May 2026 at 10.00 CEST at Advokatfirman Vinge’s office on Smålandsgatan 20 in Stockholm. Registration starts at 9.30 CEST. The shareholders may exercise their voting rights at the annual general meeting by attending […]